Advancements in Obesity Management (AOM)
Published: 20 June 2024
-
Views:
2947
-
Likes:
7
-
Views:
2947
-
Likes:
7
-
1h 4m 31s
Overview
The on-demand version of Advancements in Obesity Management (AOM) 2024 explores the intricate links between obesity and cardiovascular disease, providing key insights in evolving diagnostic and treatment strategies.
This event, led by Course Directors Dr Harold Bays (Louisville Metabolic and Atherosclerosis Research Centre, US) and Prof Naveed Sattar (University of Glasgow, UK) brings together a distinguished group of global faculty members who are renowned experts in the field of obesity and cardiovascular disease.
Split into four sessions, the faculty delve into the complexities of obesity and its multifaceted intricacies, spanning medical, surgical, nutritional, psychological and social dimensions for clinicians treating patients with obesity.
The live version of Advancements in Obesity Management was CME-accredited. This on-demand version is not.
Key Learning Objectives
- To understand the complex and multifactorial relationship between obesity and CV disease, including the biological, behavioural and environmental factors that contribute to this relationship
- To understand the impacts of obesity across the CV disease spectrum
- Apply current treatment methodologies to reduce the impact of obesity on CV disease utilising the multidisciplinary team
Target Audience
- Cardiologists
- Primary Care Physicians
- Endocrinologists
- Diabetologists
- Obesity Specialists
More from this programme
Part 1
Session 1: Obesity as a Disease, Diagnosis and Cardiovascular Disease Risk
The panel introduce a patient living with obesity, including current diagnosis and cardiovascular complications of the disease. Furthermore, the emerging data leading to a revolution in the treatment of obesity is discussed.
Part 2
Session 2: Rapid Fire Sessions - Challenges of Treating Specific CV Disease in Patients With Obesity
In the second session, the panel delve into treatment of specific CV diseases in patients living with obesity. Key co-morbidities discussed include diabetes, hypertension, dyslipidemia and thrombosis.
Part 3
Session 3: Healthful Nutrition, Physical Activity, Behaviour Modification and MDT
In this third session, the panel explore the biological, environmental, psychological and social factors contributing to obesity.
Part 4
Session 4: Medical and Procedural Options and the Referral Pathways
In the final session, the panel discuss practical considerations in utilising new pharmacological therapies for treating obesity and cover the extensive development pipeline. The current understanding of clinical outcome data and patient referral criteria are also discussed for surgical approaches.
Faculty Biographies
Naveed Sattar
Professor of Metabolic Medicine
Prof Naveed Sattar is a distinguished Professor of Metabolic Medicine at the renowned Institute of Cardiovascular and Medical Sciences, University of Glasgow. With over two decades of dedicated research and clinical experience, Prof Naveed Sattar has emerged as a leading figure in the field of metabolic medicine and cardiovascular health.
Prof Naveed Sattar's research delves into the origins, evaluation, and treatment of diabetes, obesity, and cardiovascular conditions. Collaborating with various colleagues over the past two decades, he has authored numerous impactful papers, notably with the Emerging Risk Factor Consortium and diabetes registries in Scotland and Sweden. Prof Naveed Sattar has contributed to several lifestyle-focused trials, such as DIRECT, EUROFIT, and UPBEAT, producing mechanistic insights alongside.
Harold Bays
Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.
Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association, The Obesity Society, the American College of Cardiology, the American Association of Clinical Endocrinologists, the National Lipid Association, and the American Society of Preventive Cardiology.
Dr Bays has written or served as a contributing author to over 350 scientific manuscripts and book chapters and authored/presented 100’s of scientific abstracts.
Mikhail Kosiborod
Cardiologist
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Ozden Gokdemir
Associate Professor
Ozden Gokdemir is an Associate Professor at the Izmir University of Economics - Faculty of Medicine in Izmir, Turkey. She is also Chair of the World Organisation for Family Doctors (WONCA) Working Party on Planetary Health and past lead of the special interest group on mental health at the European Young Family Doctors Movement (EYFMD).
Comments